U.S., May 27 -- ClinicalTrials.gov registry received information related to the study (NCT07605429) titled 'Phase III Clinical Study of Rugonersen in Angelman Syndrome.' on May 15.
Brief Summary: Purpose of the study is to evaluate the efficacy and safety of intrathecally administered rugonersen in pediatric and adult participants with Angelman syndrome.
Study Start Date: June, 2026
Study Type: INTERVENTIONAL
Condition:
Angelman Syndrome
Intervention:
DRUG: rugonersen
Study Drug
PROCEDURE: Sham Control
Sham Procedure
Recruitment Status: NOT_YET_RECRUITING
Sponsor: OHB Pediatrics Ltd.
Published by HT Digital Content Services with permission from Health Daily Digest....